Patients with the TT (POR *28/*28) genotype and Kidney Transplantation who are treated with tacrolimus may have an increased risk for developing new-onset diabetes after transplantation, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus.